No Data
Hainan Huluwa Pharmaceutical Unit Passes GMP Compliance Inspection
Hainan Huluwa Pharmaceutical Group (605199.SH): The wholly-owned subsidiary received the Pharmaceutical GMP compliance inspection results.
Gelonghui December 31丨Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. (hereinafter referred to as "Guangxi Weiwei") recently received the "Notification of Pharmaceutical GMP Compliance Inspection Results" issued by the Guangxi Zhuang Autonomous Region Pharmaceutical Supervision and Administration Bureau. The company has acquired the pediatric phlegm-reducing cough granules from Guangxi Wuzhou Sanjian Pharmaceutical Co., Ltd. (Announcement No.: 2023-004) and has passed the GMP compliance inspection after completing the holder change.
Hainan Huluwa Pharmaceutical Group (605199.SH): The company's PE and PB ratios are much higher than the industry average, which may indicate irrational speculation.
Gelonghui reported on December 4th that Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its stocks have been on a continuous涨停 for 7 trading days from November 26, 2024 to December 4, 2024, with a cumulative increase of 94.89%, and the turnover ratio for the last 7 trading days is 29.65%. The company's stock price rise is significantly higher than the average level of the sse composite index and the pharmaceutical manufacturing industry during the same period, which may indicate irrational speculation. The company specifically reminds investors that there has been no significant change in its fundamentals, and urges all investors to be aware of secondary market trading risks, make rational decisions, and invest prudently. As of December 3, 2024,
The hainan huluwa pharmaceutical group (605199.SH) has had a significant short-term increase in stock prices, which may be due to irrational speculation.
Hainan Huluwa Pharmaceutical Group (605199.SH) has issued a risk warning announcement stating that the company's stock price has increased significantly in the short term, which may pose...
Subdued Growth No Barrier To Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) With Shares Advancing 43%
In November, the frenzy of "mystical stock trading" is in full swing, with the strongest bull stock experiencing 15 daily limit-ups in 20 days, trading Eastern related stocks, zodiac Snake related stocks, numerical series, etc...
Attention economy.
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
No Data
